Regeneus' Progenza Stem Cell Therapy Clears Initial Safety Review

Jan. 13, 2016 5:17 PM ET
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Short Only

Contributor Since 2009

Proactiveinvestors is a leading multi-media news organisation, investor portal and events management business with offices in New York, Sydney, Toronto, Frankfurt and London. Proactiveinvestors operates five financial websites in four languages providing breaking news, comment and analysis on hundreds of listed companies across the globe daily. We are one of the fastest growing financial media portals in the world. The group also operates hugely successful “investor forums” where three or four companies present to an audience of high net sophisticated investors, fund managers, hedge funds, private client brokers and analysts. Ian Mclelland founded Proactiveinvestors in 2006 as a way to channel his own views on companies small and mid-cap public companies. What started as a hobby quickly turned into a full time job as the website's readership exploded. One2One forums were added later in 2006, and within two years the company had expanded its operations into Canada and Australia. In 2009 the company expanded into Germany and finally into the US in 2010. Proactiveinvestors is now one of the fastest growing global financial media organizations in the world receiving more than one million visitors per month, with investor forums held across the globe on a regular basis.

Regeneus' (ASX:RGS) off-the-shelf allogeneic stem cell treatment for knee osteoarthritis, Progenza, has enhanced its potential for commercialisation for the company after an encouraging review of safety data from an oversight committee in early trialling.

The regenerative medicine technology received no safety concerns after trialling with its first cohort of 10 patients in the trial.

The STEP, or Safety, Tolerability and Efficacy of Progenza, trial seeks to evaluate the treatment's safety and tolerability as well as its effect on knee pain and function.

This progress opens enrolment for a second cohort in the trial and demonstrates a positive advance towards the clinical development of the allogeneic stem cell therapy.

Cohort 2 is expected to be recruited in H1 2016.

The trial includes 20 participants with knee osteoarthritis treated at two different doses of cells.

Participants receive ultrasound-guided injections of Progenza or placebo directly into their arthritic knee joint, with one in five patients receiving a placebo injection.

About Progenza

Progenza is produced from mesenchymal stem cells (MSC) derived from the adipose (fat) tissue of a healthy donor who has been extensively screened.

Adipose tissue is readily available from donors in large quantities and has significantly higher MSCs per gram of tissue than other tissue sources such as bone marrow or cord tissue.

Adipose-derived MSCs also have the added advantage of showing greater capacity for expansion than MSCs from other tissue types.

The company's proprietary and scalable manufacturing process is capable of producing millions of therapeutic doses from one donor.

This makes for a high unmet patient need prior to joint replacement.


This is a strong start to the STEP trial which places Regeneus on the path towards providing a new treatment option for patients with osteoarthritis.

With a global market of 250 million people affected worldwide by osteoarthritis , which has no known disease modifying treatments, Progenza's progress in clinical trials will be keenly watched.

While the key focus will be to monitor Progenza's safety, the trial will also allow Regeneus to assess the treatment for preliminary efficacy as the company targets a massive osteoarthritis market that has an unmet need.

Osteoarthritis is the fastest increasing major health condition due to ageing of the population, increased obesity and lack of physical activity.

Regeneus has multiple technology platforms based on allogeneic off-the-shelf stem cells and immuno-oncology.

Significantly, the platform allows for the scalable production of off the-shelf cell products for other potential therapeutic uses.

A further catalyst and milestones for Progenza is to secure a manufacturing and development partner for Japan.

In addition to the trial's second cohort set to be in place in coming months there are a number of key R&D, clinical and commercial milestones in sight through the company's portfolio.

Proactive Investors is a global leader reporting financial news, media, research and hosts events for listed emerging growth companies and investors across four continents.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.